Zhu Bo, Zhang Chenhui, Shen Xiaolu, Chen Cong, Chen Xuanyu, Lu Yiyi, Chen Yumei, Guo Min
Department of Obstetrics and Gynecology of Wenzhou People's Hospital, The Third Affiliated Clinical Institute of Wenzhou Medical University, Wenzhou, China.
Dose Response. 2023 Mar 19;21(1):15593258231164055. doi: 10.1177/15593258231164055. eCollection 2023 Jan-Mar.
Adenomyosis is a uterine condition in which endometrial glands and stroma are commonly pathologically observed in the myometrium. In this study, we sought to determine the effect of resveratrol on the progression of adenomyosis. Adenomyosis was induced in mice given tamoxifen neonatally. All mice were subjected to body weight measurement and hotplate testing every four weeks beginning four weeks after birth. All mice with adenomyosis were randomly separated into 3 groups at 16 weeks: untreated, low-dose resveratrol (25 mg/kg), and high-dose resveratrol (50 mg/kg). After 3 weeks of treatment, final hotplate test and body weight measurement were performed, and the uterine horn blood samples were collected. Adenomyosis in mice caused body weight loss and uterine weight gain, reduced hotplate latency, and progression of endometrial fibrosis. The underlying biological process could be coupled with the overexpression of many cells' proliferation and immune-regulation-related genes. Resveratrol treatment could slow the progression of adenomyosis by enhancing hotplate latency, lowering endometrial fibrosis, and restoring cell proliferation- and immune-regulation-associated gene expression levels in endometrium and plasma. However, resveratrol treatment also reduced the body weight and uterine weight. In conclusion, Resveratrol might be a potential compound for treating patients with adenomyosis.
子宫腺肌病是一种子宫病症，其特征为在子宫肌层中通常可通过病理学观察到子宫内膜腺体和间质。在本研究中，我们试图确定白藜芦醇对子宫腺肌病进展的影响。通过给新生小鼠注射他莫昔芬诱导子宫腺肌病。从出生后四周开始，每四周对所有小鼠进行体重测量和热板试验。在16周时，将所有患有子宫腺肌病的小鼠随机分为3组：未治疗组、低剂量白藜芦醇组（25毫克/千克）和高剂量白藜芦醇组（50毫克/千克）。治疗3周后，进行最终的热板试验和体重测量，并采集子宫角血样。小鼠的子宫腺肌病导致体重减轻和子宫重量增加，热板潜伏期缩短，以及子宫内膜纤维化进展。潜在的生物学过程可能与许多细胞增殖和免疫调节相关基因的过度表达有关。白藜芦醇治疗可通过延长热板潜伏期、降低子宫内膜纤维化以及恢复子宫内膜和血浆中细胞增殖和免疫调节相关基因的表达水平来减缓子宫腺肌病的进展。然而，白藜芦醇治疗也降低了体重和子宫重量。总之，白藜芦醇可能是治疗子宫腺肌病患者的一种潜在化合物。
